SanBio’s US-based Phase 1/2a Clinical Trial of SB623 for the Treatment of Chronic Motor Deficit from Ischemic Stroke Was Addressed at an Event Held by California Institute for Regenerative Medicine (CIRM)

June 14, 2018 |

1 min read

The SanBio Groupn hereby announces that the US-based phase 1/2a clinical trial of SB623 for the treatment of chronic motor deficit from ischemic stroke

TOKYO--(BUSINESS WIRE)-- The SanBio Group (SanBio Co., Ltd. and subsidiary SanBio, Inc.), a scientific leader in regenerative medicine for neurological disorders, hereby announces that the US-based phase 1/2a clinical trial of SB623 for the treatment of chronic motor deficit from ischemic stroke conducted by the SanBio group was addressed at an event held by California Institute for Regenerative Medicine (CIRM) on May 31, 2018.

The recording of the event is available for view at https://www.facebook.com/CaliforniaInstituteForRegenerativeMedicine/

SanBio, Inc. and SanBio Co., Ltd.

SanBio group is engaged in the regenerative medicine business spanning research, development, manufacture, and sales of regenerative medicines. In regards to its propriety regenerative medicine product SB623, SanBio is conducting a phase 2b clinical trial for the treatment of chronic motor deficit from ischemic stroke in the US together with its development partner in the US and Canada, Sumitomo Dainippon Pharma Co., Ltd. On its own, SanBio is conducting a global phase 2 clinical trial of SB623 targeting chronic motor deficit from TBI in Japan and the US. Headquartered in Tokyo, SanBio has its main R&D base in Mountain View, California in the US.